Company & Sponsor Intelligence
Cerecin
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed2
Countries2
Therapeutic footprint
alzheimersother_neurology
Indexed studies
NCT01741194AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
alzheimers · United StatesPHASE2, PHASE3
alzheimers · United StatesPHASE2, PHASE3
NCT05028114Tricaprilin Liquid Formulation PK Study
alzheimers · AustraliaPHASE1
alzheimers · AustraliaPHASE1
NCT04727970Tricaprilin Infantile Spasms Pilot Study
other_neurology · AustraliaPHASE1
other_neurology · AustraliaPHASE1
NCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
alzheimers · PHASE3
alzheimers · PHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →